English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

HIV-HBV co-infection was previously studied in patients older than 40 years of age, with added risk factors for liver disease. Data on progression of liver damage in young, co-infected patients, without associated comorbidities is sparse. We assessed the prevalence and stage of HBV co-infection in young individuals with parenterally acquired HIV infection and multiple previous antiretroviral (ART) treatments. Out of 227 patients (median age: 24 years, median duration of HIV infection: 23.9 years, median ART duration: 11.6 years), 61.7% had any markers of HBV infection, 53.6% were chronic HBsAg carriers, 9.3% had HBeAg present, 11.4% had high-levels of HBV DNA and 1.4% had severe liver fibrosis according to FIB-4 noninvasive score. HBV co-infected patients had longer ART exposure (147.07 vs. 121.3 months, p = 0.003) than those with HIVin the absence of HBV, with no significant differences in the use or duration of HIV-HBV dually-active antiretrovirals (lamivudine, tenofovir). Young HIV-HBV co-infected patients remain free of hepatic disease under ART.

LIVER FUNCTION IN A COHORT OF YOUNG HIV-HBV CO-INFECTED PATIENTS ON LONG-TERM COMBINED ANTIRETROVIRAL THERAPY